Publicaciones en colaboración con investigadores/as de University of Milano-Bicocca (23)

2021

  1. Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

    Modern Pathology, Vol. 34, Núm. 1, pp. 59-69

2019

  1. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia

    Journal of Immunological Methods, Vol. 475

  2. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS

    Leukemia, Vol. 33, Núm. 9, pp. 2254-2265

  3. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study

    Leukemia, Vol. 33, Núm. 9, pp. 2241-2253

2018

  1. Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia

    Leukemia, Vol. 32, Núm. 4, pp. 874-881

2017

  1. High-throughput immunogenetics for clinical and research applications in immunohematology: Potential and challenges

    Journal of Immunology, Vol. 198, Núm. 10, pp. 3765-3774

  2. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

    Blood, Vol. 129, Núm. 3, pp. 347-357

2015

  1. Quality assessment program for EuroFlow protocols: Summary results of four-year (2010-2013) quality assurance rounds

    Cytometry Part A, Vol. 87, Núm. 2, pp. 145-156

2013

  1. The MLL recombinome of acute leukemias in 2013

    Leukemia, Vol. 27, Núm. 11, pp. 2165-2176

2011

  1. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study

    Blood, Vol. 118, Núm. 8, pp. 2077-2084

2010

  1. Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia treatment

    Leukemia

  2. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study

    Blood, Vol. 115, Núm. 16, pp. 3206-3214

  3. Standardized MRD quantification in European all trials: Proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18-20 September 2008

    Leukemia, Vol. 24, Núm. 3, pp. 521-535

2009

  1. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol

    Leukemia, Vol. 23, Núm. 6, pp. 1073-1079

2007

  1. Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The 'big sister' of the infant disease?

    Leukemia, Vol. 21, Núm. 4, pp. 642-646

  2. Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data

    Leukemia

  3. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement

    Leukemia, Vol. 21, Núm. 4, pp. 633-641

  4. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting

    Leukemia, Vol. 21, Núm. 4, pp. 706-713

2006

  1. Minimal residual disease

    CHILDHOOD LEUKEMIAS, 2ND EDITION (CAMBRIDGE UNIV PRESS), pp. 679-706

  2. Minimal residual disease

    Childhood Leukemias, Second Edition (Cambridge University Press), pp. 679-706